MAML1

Across TCGA pan-cancer cohorts, MAML1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MAML1 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MAML1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MAML1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, LSCC, and CCRCC are the cancer types where MAML1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.814	0.425	.036	4	view →
LSCC	DFS	Tertile	II,III,IV	0.556	0.835	.036	3	view →
CCRCC	DFS	Tertile	All	1.000	0.832	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MAML1–LUAD (OS)

Open the LUAD breakdown →